BI Asset Management Fondsmaeglerselskab A S Lowers Stake in Halozyme Therapeutics, Inc. $HALO

BI Asset Management Fondsmaeglerselskab A S cut its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 35.1% in the 3rd quarter, Holdings Channel reports. The fund owned 288,952 shares of the biopharmaceutical company’s stock after selling 155,995 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Halozyme Therapeutics were worth $21,192,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Root Financial Partners LLC bought a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at about $25,000. Richardson Financial Services Inc. boosted its stake in Halozyme Therapeutics by 87.6% in the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 198 shares in the last quarter. Newbridge Financial Services Group Inc. bought a new position in Halozyme Therapeutics during the second quarter valued at approximately $32,000. Employees Retirement System of Texas purchased a new position in shares of Halozyme Therapeutics during the second quarter worth approximately $34,000. Finally, Penserra Capital Management LLC bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth approximately $52,000. Institutional investors own 97.79% of the company’s stock.

Insider Activity

In other news, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the sale, the director owned 40,123 shares of the company’s stock, valued at approximately $2,818,640.75. The trade was a 4.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Helen Torley sold 16,569 shares of the stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $68.92, for a total transaction of $1,141,935.48. Following the completion of the transaction, the chief executive officer directly owned 708,719 shares of the company’s stock, valued at approximately $48,844,913.48. The trade was a 2.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 41,398 shares of company stock valued at $2,861,352. Corporate insiders own 2.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Leerink Partners upgraded shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 target price on the stock in a research report on Tuesday, October 14th. TD Cowen lifted their price objective on Halozyme Therapeutics from $79.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Tuesday, November 4th. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday. Finally, Morgan Stanley dropped their price objective on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research note on Monday, October 20th. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics has a consensus rating of “Hold” and an average target price of $78.80.

Halozyme Therapeutics Price Performance

Shares of HALO stock opened at $77.93 on Thursday. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. Halozyme Therapeutics, Inc. has a fifty-two week low of $47.50 and a fifty-two week high of $79.50. The firm has a market cap of $9.16 billion, a P/E ratio of 16.41, a P/E/G ratio of 0.32 and a beta of 0.97. The business’s 50 day moving average price is $69.12 and its 200-day moving average price is $68.84.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.63 by $0.09. The business had revenue of $354.26 million for the quarter, compared to analysts’ expectations of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The firm’s revenue for the quarter was up 22.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.27 earnings per share. On average, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Halozyme Therapeutics News Roundup

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised multiple quarterly and annual EPS forecasts (notably FY2026 to $7.43 from $6.22 and FY2027 to $8.18 from $7.57), reflecting stronger forward profit expectations that can support a higher valuation. See MarketBeat summary of the Zacks notes. MarketBeat: HALO coverage
• Positive Sentiment: Zacks also lifted several near‑term quarter estimates (Q1–Q4 2026 and multiple quarters in 2027), signalling anticipated stronger revenue/earnings momentum that likely helped investor sentiment. See MarketBeat summary of the Zacks notes. MarketBeat: HALO coverage
• Positive Sentiment: Coverage highlighting Halozyme as an attractive long‑term/value investment (Zacks style score write‑up) bolsters the buy case for value‑oriented investors. Why Halozyme is a Top Value Stock (Zacks)
• Positive Sentiment: An investor piece arguing that recent acquisitions position Halozyme for longer‑term growth supports the strategic narrative beyond near‑term numbers and may attract growth investors. Halozyme: Key Acquisitions (Seeking Alpha)
• Neutral Sentiment: Zacks’ reports reiterate a wide range of forward estimates — consensus figures cited in summaries differ from Zacks’ own upgraded forecasts — so investors should watch upcoming company disclosures for confirmation. MarketBeat: HALO coverage
• Negative Sentiment: One small downgrade: Zacks trimmed Q3 2027 EPS slightly (from $2.02 to $1.99) — a minor data point but a reminder that not every quarter was raised. MarketBeat: HALO coverage

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.